XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS MEASURED AT FAIR VALUE
6 Months Ended
Jun. 30, 2022
Investments, All Other Investments [Abstract]  
INVESTMENTS MEASURED AT FAIR VALUE

12. INVESTMENTS MEASURED AT FAIR VALUE

 

Financial assets measured at fair value on a recurring basis are summarized below and disclosed on the condensed consolidated balance sheet as of June 30, 2022 and December 31, 2021:

 

   Amount at   Fair Value Measurement Using   Amount at 
   Cost   Level 1   Level 2   Level 3   Fair Value 
June 30, 2022                         
Assets                         
Investment Securities- Fair Value  $76,264,051   $17,132,071   $         -   $           -   $17,132,071 
Investment Securities- Trading   2,387,149    3,466,845    -    -    3,466,845 
Convertible Note Receivable   138,599    -    -    88,684    88,684 
Warrants - American Premium Mining   -    -    -    507,062    507,062 
                          
Total  $78,789,799   $20,598,916   $-   $595,746   $21,194,662 
                          
Investment Securities - Fair Value NAV as Practical Expedient                       24,112 
                          
Total Investment in securities at Fair Value                       21,218,774 

 

 

   Amount at   Fair Value Measurement Using   Amount at 
   Cost   Level 1   Level 2   Level 3   Fair Value 
December 31, 2021                         
Assets                         
Investment Securities- Fair Value  $72,000,301   $25,320,694   $          -   $-   $25,320,694 
Investment Securities- Trading   9,809,778    9,908,077    -    -    9,908,077 
Convertible Note Receivable   138,599    -    -    98,398    98,398 
Warrants - American Premium Mining   696,791    -    -    1,009,854    1,009,854 
Warrants - AMRE   -    -    -    -    - 
                          
Total Investment in securities at Fair Value  $82,645,469   $35,228,771   $-   $1,108,252   $36,337,023 

 

Realized loss on investment securities for the six months ended June 30, 2022 was $6,355,451 and realized gain on investment securities for the six months ended June 30, 2021 was $296,961. Unrealized loss on securities investment was $10,766,390 and $30,703,914 in the six months ended June 30, 2022 and 2021, respectively. These gains and losses were recorded directly to net income (loss). The change in fair value of the convertible note receivable in the six months ended June 30, 2022 and 2021 was $9,714 and $37,909, respectively, and was recorded in condensed consolidated statements of stockholders’ equity.

 

For U.S. trading stocks, we use Bloomberg Market stock prices as the share prices to calculate fair value. For overseas stock, we use the stock price from the local stock exchange to calculate fair value. The following chart shows details of the fair value of equity security investment at June 30, 2022 and December 31, 2021, respectively.

 

   Share price       Market Value    
   6/30/2022   Shares   6/30/2022   Valuation
                
DSS (Related Party)  $0.351    41,446,087   $14,547,577   Investment in Securities at Fair Value
                   
AMBS (Related Party)  $0.002    20,000,000   $48,000   Investment in Securities at Fair Value
                   
Holista (Related Party)  $0.021    43,596,621   $931,552   Investment in Securities at Fair Value
                   
American Premium Mining (Related Party)  $0.001    354,039,000   $389,443   Investment in Securities at Fair Value
                   
Value Exchange  $0.187    6,500,000   $1,215,500   Investment in Securities at Fair Value
                   
Trading Stocks            $3,466,845   Investment in Securities at Fair Value
                   
Total Level 1 Equity Securities   $20,598,917    
                   
Nervotech   N/A    1,666   $37,045   Investment in Securities at Cost
Hyten Global   N/A    3,800   $42,562   Investment in Securities at Cost
Ubeauty   N/A    3,600   $19,609   Investment in Securities at Cost
    Total Equity Securities   $20,698,133    

 

 

    Share price           Market Value      
    12/31/2021     Shares     12/31/2021     Valuation
                       
DSS (Related Party)   $ 0.672       19,888,262     $ 13,364,912     Investment in Securities at Fair Value
                             
AMBS (Related Party)   $ 0.016       20,000,000     $ 328,000     Investment in Securities at Fair Value
                             
Holista (Related Party)   $ 0.034       43,626,621     $ 1,489,179     Investment in Securities at Fair Value
                             
American Premium Mining (Related Party)   $ 0.002       354,039,000     $ 778,886     Investment in Securities at Fair Value
                             
True Partner   $ 0.119       62,122,908     $ 7,409,717     Investment in Securities at Fair Value
                             
Value Exchange   $ 0.300       6,500,000     $ 1,950,000     Investment in Securities at Fair Value
                             
Trading Stocks                   $ 9,908,077     Investment in Securities at Fair Value
                             
  Total Level 1 Equity Securities     $ 35,228,771      
                       
Nervotech      N/A       1,666     $ 37,045      Investment in Securities at Cost
Hyten Global      N/A       3,800     $ 42,562      Investment in Securities at Cost
Ubeauty      N/A       3,600     $ 19,609      Investment in Securities at Cost
      Total Equity Securities     $ 35,327,987      

 

DSS convertible preferred stock

 

During the six months ended June 30, 2021, Global BioMedical Pte Ltd. converted 42,575 preferred stock of DSS into 6,570,170 common shares of DSS.

 

Sharing Services Convertible Note

 

The fair value of the Sharing Services Convertible Note under level 3 category as of June 30, 2022 and December 31, 2021 was calculated using a Black-Scholes valuation model valued with the following weighted average assumptions:

 

  

June 30,

2022

  

December 31,

2021

 
         
Dividend yield   0.00%   0.00%
Expected volatility   126.23%   138.85%
Risk free interest rate   3.25%   3.25%
Contractual term (in years)   0.51    0.76 
Exercise price  $0.15   $0.15 

 

 

We assumed dividend yield rate is 0.00% in Sharing Services. The volatility is based on the historical volatility of the Sharing Services’ common stock. Risk-free interest rates were obtained from U.S. Treasury rates for the applicable periods.

 

Changes in the observable input values would likely cause material changes in the fair value of the Company’s Level 3 financial instruments. A significant increase (decrease) in this likelihood would result in a higher (lower) fair value measurement.

 

The table below provides a summary of the changes in fair value which are recorded as other comprehensive income (loss), including net transfers in and/or out of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three and six months ended June 30, 2022 and 2021:

 

   Total 
Balance at January 1, 2022  $1,108,252 
Total losses   (203,463)
Balance at March 31, 2022  $904,789 
Total losses   (591)
Balance at June 30, 2022  $904,198 

 

   Total 
Balance at January 1, 2021  $66,978 
Total losses   (1,987)
Balance at March 31, 2021  $64,991 
Total losses   (35,922)
Balance at June 30, 2021  $29,069 

 

Vector Com Convertible Bond

 

On February 26, 2021, the Company invested approximately $88,599 in the convertible bond of Vector Com Co., Ltd (“Vector Com”), a private company in South Korea. The interest rate is 2% per annum and maturity is two years. The conversion price is approximately $21.26, per common share of Vector Com. As of June 30, 2022, the management estimated that the fair value of this note remained unchanged from its initial purchase price.

 

Warrants

 

On March 2, 2020 and October 29, 2021, the Company received warrants to purchase shares of AMRE, a related party private company, in conjunction with the Company lending two $200,000 promissory notes. For further details on this transaction, refer to Note 8 - Related Party Transactions, Note Receivable from a Related Party Company. As of June 30, 2022 and December 31, 2021, AMRE was a private company. Based the management’s analysis, the fair value of the warrants was $0 as of December 31, 2021. All warrants were converted into common shares in March 2022.

 

On July 17, 2020, the Company purchased 122,039,000 shares, approximately 9.99% ownership, and 1,220,390,000 warrants with an exercise price of $0.0001 per share, from APM, for an aggregated purchase price of $122,039. During 2021, the Company exercised 232,000,000 of the warrants to purchase 232,000,000 shares of APM for the total consideration of $232,000, leaving the balance of outstanding warrants of 988,390,000 at December 31, 2021. The Company did not exercise any warrants during six months ended June 30, 2022. We value APB warrants under level 3 category through a Black Scholes option pricing model and the fair value of the warrants from APM was $507,062 as of June 30, 2022 and $1,009,854 as of December 31, 2021.

 

 

The fair value of the APM warrants under level 3 category as of June 30, 2022 and December 31, 2021 was calculated using a Black-Scholes valuation model valued with the following weighted average assumptions:

 

           
  

June 30,

2022

  

December 31,

2021

 
         
Stock Price  $0.0011   $0.0022 
Exercise price   0.001    0.001 
Risk free interest rate   1.46%   1.48%
Annualized volatility   155.6%   186.5%
Year to maturity   8.07    8.58